Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;104(2):e15616.
doi: 10.1111/tan.15616.

HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patients

Marco Andreani  1 , Feliciana Mariotti  2 , Anna Pira  2 , Franco Locatelli  3   4 , Giuseppe Testa  1 , Mariarosa Battarra  1 , Priscilla Caputi  2 , Alessandra Scarabello  5 , Barbara Bellei  6 , Cristiana Di Campli  7 , Maria Chiara Collina  7 , Ilaria Esposito  8 , Anna Rita Giampetruzzi  9 , Biagio Didona  10 , Dario Pitocco  3   11 , Clara De Simone  3   8 , Giovanni Di Zenzo  2
Affiliations

HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patients

Marco Andreani et al. HLA. 2024 Aug.

Abstract

Bullous pemphigoid (BP), although a rare disease, is the most frequent subepidermal autoimmune disorder. Treatment with gliptins, used for type 2 diabetes, was reported as associated with BP onset. To identify HLA alleles that may reflect a higher susceptibility to BP in the Italian population, we analysed 30 patients affected by idiopathic bullous pemphigoid (IBP) and 86 gliptin-associated BP (GABP) patients. A significant association between HLA-DQB1*03:01 allele and IBP and GABP patients was found. Of note, both IBP and GABP were significantly associated with one of the following haplotypes: DRB1*11:01, DRB3*02:02, DQA1*05:05, DQB1*03:01 or DRB1*11:04, DRB3*02:02, DQA1*05:05 and DQB1*03:01. These data identify, for the first time, potential markers of susceptibility to BP in the Italian population, especially when associated with gliptin intake.

Keywords: HLA‐DQB1*03:01; bullous pemphigoid; gliptin.

PubMed Disclaimer

References

REFERENCES

    1. Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019;10:1506. doi:10.3389/fimmu.2019.01506
    1. Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020;10:1432. doi:10.3390/biom10101432
    1. Merli M, Accorinti M, Romagnuolo M, et al. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. Front Med (Lausanne). 2023;10:1208418. doi:10.3389/fmed.2023.1208418
    1. Salemme A, Fania L, Scarabello A, et al. Gliptin‐associated bullous pemphigoid shows peculiar features of anti‐BP180 and ‐BP230 humoral response: results of a multicenter study. J Am Acad Dermatol. 2022;87:56‐63. doi:10.1016/j.jaad.2022.02.036
    1. Lindgren O, Varpuluoma O, Tuusa J, et al. Gliptin‐associated bullous pemphigoid and the expression of dipeptidyl peptidase‐4/CD26 in bullous pemphigoid. Acta Derm Venereol. 2019;99:602‐609. doi:10.2340/00015555‐3166

Publication types

LinkOut - more resources